With the changing pharmacy practice landscape, the provision of (and billing for) clinical services is becoming increasingly important. We conducted this research to provide a complete picture of remuneration programs in place for these services worldwide, to serve as an update to previous work published in 2008 
Introduction
Since the first definition of pharmaceutical care was published over 20 years ago, 1 the pharmacy profession has aimed to transition from a distributive focus to a patient care focus. In particular, the past decade has seen a significant expansion of the pharmacists' role through the implementation of services such as minor ailments schemes, prescribing, medication therapy management programs and the authorization to administer drugs and vaccines by injection. The Blueprint for Pharmacy, a Canadian strategy for improving the provision of patientcentred care by pharmacists, identifies obtaining remuneration for professional services as a key area of action to support such activities. 2 Indeed, lack of remuneration for services has been cited by community pharmacists as a key barrier preventing the greater provision of clinical services. 3, 4 As the pharmacy practice literature reporting the clinical benefits of pharmacist cognitive services continues to grow 5, 6 and pharmacy revenues from dispensing alone decrease in light of generic drug price reductions and other factors, the profession is advocating for appropriate payment for clinical services.
A systematic review published by members of our group in 2008 identified 28 programs worldwide wherein pharmacists received remuneration for clinical care services, most often funded by government payers. 7 Medication therapy management, a type of clinical care service defined as a medication review with resolution of drug-related problems, was the most common remunerated service, ranging from $27 to $170 depending on the number of problems resolved and the time spent, among other factors. While only 14 of these programs reported clinical or economic outcomes, these services were consistently associated with improved chronic disease control and cost-effectiveness. Since the publication of the original review, many additional remuneration systems have been developed, implemented and evaluated. This article therefore aims to serve as an update to the previous publication, presenting the current status of pharmacist remuneration for clinical care activities worldwide.
Methods
The QUORUM process for the conduct and reporting of systematic reviews was followed. 8 As with the previous review, pharmacist clinical care services were defined as "those that enhanced a patient's medication therapy or overall health and did not include medication preparation, distribution or any tasks that could be delegated to a typical Canadian pharmacy technician with basic training. " 7 The provision of routine medication counseling upon dispensing was excluded from this review, as was routine clozapine monitoring without intervention or care plan development and the administration of drugs or vaccines by injection, which has been reported separately. 9 In consultation with a medical librarian, we performed searches in Ovid MEDLINE, Ovid Embase, International Pharmaceutical Abstracts, the Cochrane Library, EconLIT, Scopus and Web of Science. The searches combined relevant keywords and subject headings (when available), including fees, reimbursement, community pharmacy services, medication therapy management, pharmaceutical care and direct patient care, among others. The complete search strategy can be obtained from the authors on request. The search strategy was derived from that employed in the 2008 review by Chan et al., 7 but expanded the number of terms used with regard to specific types of cognitive services offered, including home visits and medication therapy management. Explosion of subject headings, adjacency searching and truncation of terms were used where appropriate. The Ovid searches were peer-reviewed by a second health sciences librarian to ensure accuracy and comprehensiveness. To identify additional relevant articles, the bibliographies of included studies were manually reviewed and tables of contents for pharmacy practice journals were reviewed for additional citations.
Grey literature searches were conducted using the same search terms in the Web of Science Conference Proceedings Citation Index and ProQuest Dissertations and Theses. Following the identification of articles and grey literature, comprehensive online searches were performed to seek additional information on programs described in the citations identified and to identify additional programs not reported in the literature. Online searches encompassed accessing websites of governments and regional
KNOWLEDGE INTO PRACTICE
• Eligibility criteria, program requirements and fees offered for clinical services are highly variable across jurisdictions.
• Few programs collect data on the uptake, time required, clinical effectiveness and economic outcomes of these services-an important piece in demonstrating return on investment.
• Pharmacists are encouraged to take advantage of billing opportunities available to demonstrate the need for such services and to advocate for the need to collect patient and health system outcomes concurrently.
pharmacy associations for each province and state in Canada and the United States, Australia and Europe. The search engine Google was then used to identify any additional programs, incorporating the same search terms as applied to the database searches. Citations were identified up to December 2012 and were included if they described remuneration programs for pharmacist clinical care services in any setting and were not included in the previous review. Included articles had to be published in English and had to report on a program where remuneration for these services was provided by a third-party payer such as a government, employer or insurance plan and must be separate from dispensing fees. Programs or services paid for directly by patients were excluded, as were programs that existed solely within the context of a funded research study or pilot project, or involved fewer than 3 pharmacies. We used this approach to focus on the long-term support of pharmacists' clinical care services from a broad health care system perspective, rather than through individual pharmacy contracts with private insurers or patients or through shortterm demonstration projects.
Two authors independently screened titles and abstracts for inclusion. Disagreement was resolved by discussion and consensus. Data extraction was performed by one author and then independently verified by a second author. To facilitate comparison, all reported remuneration amounts and cost outcomes were converted to Canadian dollars using the Bank of Canada currency conversion rates as of September 16, 2013. Due to expected heterogeneity in this subject area and among different health systems, data were collected descriptively.
Results
As reported in Appendix 1 (available online at cph.sagepub.com/supplemental), 33 articles and 85 web resources describing 60 programs met our inclusion criteria and are therefore included in this review. Programs were identified across Canada, the United States, Europe, Australia and New Zealand, ranging in complexity from emergency contraception counseling to minor ailments schemes and comprehensive medication management. While many programs operate at a regional level, nationwide programs exist in all countries with the exception of Canada.
The identified programs and associated fees, with information on patient eligibility criteria, payers, implementation dates and additional pharmacist training requirements, are presented in Table 1 . Additional remuneration programs identified, but lacking information on fee amounts, are presented in Table 2 .
Payers
The majority (73%) of remunerated clinical care services identified are paid for by government agencies, with the remainder funded by private insurance plans. All third-party-funded programs, with the exception of the General Motors smoking cessation program in Canada, were based in the United States.
Types of service and remuneration schedules
The most common remunerated service identified was for completion of a medication review with or without care plan development, with 38 programs identified. Of these, 18 had limitations on the patients who qualified for the service, described in Table 3 . The average fee in North America for a medication review-determined by taking the flat fee offered for medication reviews where applicable, or assuming a 30-minute duration for those where payment was time dependentis $68.86 (SD $27.42) and pharmacists are eligible for, on average, $23.37 (SD $6.80) for performing a follow-up visit after the completion of a medication review. (All figures are given in Canadian dollars.) North American programs were selected specifically for this determination since pharmacist wages and, therefore, fees provided were more likely to be comparable. 
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Other common remuneration programs identified were for contacting prescribers about drug therapy problems identified (n = 13), smoking cessation counseling (n = 9), diabetes management (n = 5), emergency hormonal contraception counseling (n = 2) and device training for inhaled medications (n = 2). Minor ailments programs are operational in Saskatchewan, England and Northern Ireland. 23, [114] [115] [116] Seven programs paid pharmacists for prescription adaptation services, including therapeutic substitution, dose or dosage form changes, emergency prescribing or extending refills. The fee for prescription adaptation services (currently offered only in North America) averages $15.16 (SD $9.12) per service. When remuneration was provided based on a prespecified time increment, this fee was found to be on average $1.68 (SD $0.75) per minute.
Additional pharmacist training requirements
Fourteen programs (23%) required pharmacists to complete additional training or certification to provide services, including basic training on administration of the program, 22, [83] [84] [85] [99] [100] [101] [102] attendance at a workshop or completion of an online module on the disease state involved, 22, 23, 25, [55] [56] [57] [58] 82, [103] [104] [105] [106] [107] [108] credentials of a Certified Diabetes Educator or Board Certified Pharmacotherapy Specialist [30] [31] [32] [33] [42] [43] [44] [45] [46] or completion of a residency or certificate program. [30] [31] [32] [33] 79, 80 In Alberta, pharmacists with Additional Prescribing Authorization can claim higher fees for medication reviews and followups than those without this authorization, 10 and in Saskatchewan, pharmacists with PACT (Partnership to Assist with Cessation of Tobacco) training can claim for smoking cessation counseling visits of longer duration than those without PACT training. 23 One program restricted program participation to pharmacists graduating after 1996.
52,53
Evaluation of outcomes Patient and/or pharmacist uptake data, clinical or economic outcomes and barriers preventing further expansion or service provision were identified for 16 programs, representing 27% of all programs identified, and are presented in Appendix 2 (available online at cph.sagepub .com/supplemental). Presence of specific chronic conditions: 5
• Asthma (n = 4)
• Cardiovascular disease (including hypertension, heart failure, ischemic heart disease, dyslipidemia) (n = 4)
• Mental health disorder (including addiction) (n = 3)
• Diabetes (n = 4)
• Chronic obstructive pulmonary disease (n = 3)
• Others: chronic kidney disease, obesity, gastroesophageal reflux disease, sickle cell anemia (n = 1 for each)
Patient age 3
Multiple prescribers 3
Drugs requiring laboratory monitoring 2
Need for compliance packaging 2
Minimum annual drug costs 1
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Concerns with low uptake by pharmacists were reported across multiple studies. For example, the Wisconsin Medicaid Pharmaceutical Care Program found that 37% of pharmacies participated in the program for only 1 year. 88 Similarly, in New Zealand, only half of pharmacists accredited to perform medication use reviews were actually performing that service regularly. 103 Patient uptake of pharmacist clinical care services was also highly variable. At the lower end, only 17% of patients eligible for the Iowa Priority program and with prescription drug claims received a brown bag medication review. 41 Conversely, 12 pharmacists in Texas saw 500 diabetic patients within 6 months, 80 and Scottish pharmacists provided smoking cessation services to 12,000 patients per year. 104, 105 When provided, pharmacist services were effective for smoking cessation, 25, 104, 105 identifying and resolving drug-related problems, 50, 51, 66, 94, 139, 141 and improving clinical parameters such as glycosylated hemoglobin (HbA1c), cholesterol and blood pressure. 45, 50, 51, 69, 81, 95 However, 1 study of Medicare Part D medication therapy management services found mixed clinical outcomes. 142 Pharmacist services were also widely considered to have a net cost benefit, 50, 66, 70, 71, 80, 81, 94, 140, [142] [143] [144] [145] with estimated returns on investment from the payer perspective ranging from $1.29 per dollar spent within the Minnesota Medication Therapy Management Program 50 to $2.50 per dollar spent in a Medicare Part D Medication Therapy Management Program. 144 Patient satisfaction, when measured, was high, 50, 142, 146, 147 as was job satisfaction among U.K. pharmacists performing Medication Use Reviews. 112 Barriers identified by pharmacists as impeding the uptake and success of remunerated clinical care services include low reimbursement rates, cumbersome billing processes, time constraints, lack of privacy in the pharmacy, insufficient publicity regarding the availability of services and lack of interest among physicians and patients. 42, 88, 103, 112, 148 Patients noted lack of privacy to be a barrier to seeking minor ailments advice from pharmacists in England.
148
Discussion
We identified 118 records describing 60 remunerable pharmacist clinical care services across North America, Europe, Australia and New Zealand. Remunerated services included medication reviews, chronic disease management, prescription adaptations, emergency hormonal contraception counseling, smoking cessation counseling and minor ailment programs. Some regions in the United States also paid pharmacists for contacting prescribers to resolve drug therapy problems or to authorize the substitution of more cost-effective therapies.
In the 5 years since our previous review, 7 the number of remunerated pharmacist clinical care services programs described in the literature has shown expansion, although one cannot rule out that some additional citations may have been identified through our use of an expanded search strategy. Consistent with previous findings, nearly three-quarters of programs are paid for by government payers, with the remainder being supported by private insurance companies. One disturbing finding is that the proportion of programs reporting uptake and outcome data has declined from 50% to 27% in the current review. Although these findings may be limited by the few programs collecting such data internally, to remain sustainable, uptake and outcome data are critical to demonstrate a return on investment in these services from a payer perspective, to encourage expansion of remunerated programs and to demonstrate the impact of pharmacist care on patient care and health system outcomes. Processes to both collect and publish this information should therefore be built into every remuneration program. Although lack of remuneration is a commonly expressed barrier preventing pharmacists from providing more clinical care services, outcome data presented here suggest that the mere presence of a remuneration scheme is insufficient to ensure uptake in practice. For example, pharmacist participation in the remuneration programs described herein was found to vary considerably, with some programs reporting very low numbers of participating pharmacies 51, 149, 150 and others reporting a high initial expression of interest but short persistence or very low patient enrollment over time. 25, [87] [88] [89] 103, 112 Payers should consider the commonly reported barriers to uptake, including insufficient remuneration for services offered, cumbersome paperwork and complicated claims submission processes, when designing and evaluating programs. Practicing front-line pharmacists should be invited to these discussions and
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processes should be pilot-tested prior to rollout to identify and resolve administrative issues. For other barriers such as insufficient privacy in the pharmacy, time constraints and insufficient public awareness of services, employers and payers should expect that there may be some changes needed to the pharmacy layout, workflow and marketing strategy. However, one cannot rule out that some pharmacists may report the presence of a number of external barriers when motivation and other internal barriers are the primary issue. Pharmacists often lack confidence and are risk averse. 151, 152 Social cognitive theories may offer insight into the resistance to change, as they have been shown to reliably explain intention and predict the behaviour of health professionals. For example, Herbert et al. 153 used the theory of planned behavior to predict pharmacist uptake of Medicare medication management services. The theory helped identify that the most significant predictor of uptake was the "subjective norm, " or the pharmacist's perception of whether others think the service should be delivered.
Due to the high degree of heterogeneity among programs, this study was limited to the descriptive review of remunerated clinical care programs described in the literature or online. Given that over 70% of the references we identified that describe such programs are online resources and considering the large number of potential government and private insurance payers, it cannot be assured that our review captured all programs in existence worldwide. Publication bias, where programs with neutral or negative outcomes did not seek publication, also cannot be ruled out. The search may also not have identified private plans that reimburse patients' out-of-pocket costs for clinical services by pharmacists through Health Spending Accounts or other flexible accounts. Additionally, heterogeneity among fee schedules, patient eligibility, reporting methodologies and outcomes collected precluded the metaanalysis of outcomes achieved and whether a relationship exists between the payment models and/or remuneration amount and the uptake of programs or outcomes. While the limited outcome data identified suggest that pharmacistprovided clinical care services can improve patient adherence and markers of chronic disease, future research should consider whether improvements in these surrogate outcomes actually translate into improvements in hard outcomes, such as major cardiovascular events, hospitalizations or mortality. The effect of these clinical care services on patient quality of life has also been insufficiently studied to date. To address these knowledge gaps, we recommend that rigorous outcome reviews by a third party be included in programs' implementation plans, using regular cycles of evaluation and revision to improve program effectiveness.
With diminishing revenues from dispensing, remuneration models for clinical care services should also consider pharmacies' changing business models from primarily dispensingbased revenues to a blend of dispensing and patient care reimbursement income. Pharmacist opinion surveys have suggested that pharmacists often consider the fees to be insufficient, considering the time required to provide patient care. 42 Only 3 programs reported the mean time spent by pharmacists providing patient care, 95, 103, 142 with medication use reviews in New Zealand taking twice as long to perform on average (57 minutes) than expected (30 minutes) according to the payment policy. 103 More research is therefore needed to establish if fees are commensurate with the cost required to provide the service from the pharmacy's perspective or, perhaps, if pharmacists need to provide services in a more time-efficient manner. Opportunities to streamline processes and improve efficiency should also be explored. Reported returns on investment of $1.29 to $2.50 per dollar spent by these programs 50, 143 suggest that there may be room to more fairly compensate pharmacists for these services and encourage greater uptake while still remaining cost-effective, although conversely, high fees may be a deterrent for potential payers. Additionally, readers must exercise caution when interpreting ROI data from other countries in the landscape of Canada's universal health care system. As costs and savings may be realized from different perspectives (provincial Ministry of Health vs private insurance), observed outcomes may be due to a shift in costs or savings from one payer to another.
Conclusion
Despite a doubling in the worldwide number of remunerated pharmacy clinical care services described in the literature since 2006, the types of services included and the fees offered continue to vary significantly even within similar geographic CLINICAL REVIEW areas, and evaluation data remain sparse, inconsistently collected and reported. Expanding pharmacist scopes of practice worldwide and diminishing revenues from dispensing activities suggest that these programs will take on a larger role in pharmacy business models in the future. In addition to ensuring that payers adequately reimburse pharmacists for the time spent providing this cost-effective care and that patient inclusion criteria are sufficiently broad to ensure access to care, pharmacists must also make both physical and workflow-related changes to their practices to be able to accommodate these increasingly important activities. ■ From the EPICORE Centre/COMPRIS (Houle, Tsuyuki) 
